agilon health vs Sotera Health
AGL and SHC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGL and SHC compare
Sotera Health is the larger company, worth 2.4 times as much as agilon health ($4.7B against $1.9B).
Sotera Health grew revenue faster over the last twelve months (8.1% versus 2.0% for agilon health).
Sotera Health keeps more of each dollar of sales as profit, with a net margin of 13.4% compared with −1.5% at agilon health.
Sotera Health scores higher on the StockData Score (7 against 4 for agilon health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGL | SHC |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $4.7B |
| Share price | $115.66 | $16.61 |
| Change, 1 year | 637% | 2.2% |
| Change, 5 years | −80.5% | −26.3% |
| Beta (5Y) | 1.28 | 1.59 |
| Employees | 856 | 3,000 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 29.1× |
| P/S | 0.3× (better) | 3.9× |
| P/B | – | 7.1× |
| P/FCF | – | 42.1× |
| FCF yield | −0.88% | 2.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 2.0% | 8.1% (better) |
| Revenue growth, 5Y average | 37.2% (better) | 7.3% |
| Net income growth (TTM) | – | 581% |
| EPS growth (TTM) | – | 613% |
| Profitability | ||
| Gross margin | – | 55.0% |
| Operating margin | −2.6% | – |
| Net margin | −1.5% | 13.4% (better) |
| FCF margin | −0.28% | 9.3% (better) |
| Return on equity | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 3.21 |
| Interest coverage | −22.4× | – |
| Current ratio | 1.13 | 2.80 (better) |
| Altman Z-score | 2.87 (better) | 1.40 |
| Piotroski F-score | 2 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.8% | 103% |
| Held by insiders | 10.1% | – |
| Insider net buying, 12 months | $300K (better) | −$1.8B |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 5.6% | – |
Go deeper
- AGL stock overview
- AGL income statement
- AGL valuation and score
- SHC stock overview
- SHC income statement
- SHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.